Last reviewed · How we verify
PankoMab-GEX™
At a glance
| Generic name | PankoMab-GEX™ |
|---|---|
| Also known as | gatipotuzumab, Gatipotuzumab |
| Sponsor | Glycotope GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PankoMab-GEX™: Phase 1 Dose Escalation Study (PHASE1)
- PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PankoMab-GEX™ CI brief — competitive landscape report
- PankoMab-GEX™ updates RSS · CI watch RSS
- Glycotope GmbH portfolio CI